CareFusion Corp. has issued the following statement regarding a previously disclosed settlement agreement: "Today, the U.S. Department of Justice and the Office of Inspector General of the Department of Health and Human Services announced a final settlement agreement with CareFusion to resolve government investigations related to the company's prior sales and marketing practices for its ChloraPrep® skin preparation product and its relationships with health care professionals. CareFusion previously disclosed on April 25, 2013, it had reached an agreement in principle to pay the government approximately $41 million to resolve the allegations. Today's announcement finalizes the matter."
"We are pleased to resolve this matter and are confident we have strong practices, processes and controls in place," says Kieran T. Gallahue, chairman and CEO. "We have made significant investments during the past several years to improve our quality and compliance systems, including our sales and marketing practices, and will continue to do so as part of our commitment to adhering to the highest standards and aligning with best global practices."
In connection with this announcement, the company paid the settlement, which was previously reserved during the third quarter of fiscal 2013 (ended March 31, 2013).
Source: CareFusion Corp.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.